AG-4 has been characterized as a nicotinic agonist by binding (K(i) = 26 ± 1.4 μM) and in vitro functional assays. The antinociceptive effect of AG-4 was examined in mice and rats, using the hot plate, abdominal constriction, and paw-pressure tests. In both species , AG-4 (25-150 μg per mouse icv; 100-150 μg per rat icv) produced significant antinociceptive which was prevented by mecamylamine (2 mg kg-1 ip) and pempidine (3 mg kg-1 i.p.). In the antinociceptive dose range, AG-4 did not impair mice motor coordination and spontaneous motility as well as inspection activity. The present results have shown that AG-4 is a compound endowed with antinociceptive properties mediated via nicotinic activation and may be a promising beginning for new nicotinic agonists.
Antinociceptive property of the nicotinic agonist AG-4 in rodents
BOREA, Pier Andrea;
1997
Abstract
AG-4 has been characterized as a nicotinic agonist by binding (K(i) = 26 ± 1.4 μM) and in vitro functional assays. The antinociceptive effect of AG-4 was examined in mice and rats, using the hot plate, abdominal constriction, and paw-pressure tests. In both species , AG-4 (25-150 μg per mouse icv; 100-150 μg per rat icv) produced significant antinociceptive which was prevented by mecamylamine (2 mg kg-1 ip) and pempidine (3 mg kg-1 i.p.). In the antinociceptive dose range, AG-4 did not impair mice motor coordination and spontaneous motility as well as inspection activity. The present results have shown that AG-4 is a compound endowed with antinociceptive properties mediated via nicotinic activation and may be a promising beginning for new nicotinic agonists.I documenti in SFERA sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
